Re-Evaluation of the Architecture Built During the 1920-1940 Period In
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Introduction
FLUSSER STUDIES 28 Introduction The current issue of Flusser Studies considers Flusser’s first three years in Europe and focuses on Merano/Meran in northern Italy. There, Vilém and Edith spent the falls and winters between October 1972 and May 1975, reading and writing in a more or less quiet ambience. As Flusser wrote in a letter to Abraham Moles on December 4 1973 „All very well, but what should we be doing? My answer: stay put in Merano or a farmhouse near Strasbourg, write books and articles nobody will read, talk together about God and the world, and have a nice time as the fires are burning. I invite you to do this with us“.1 However, this account of a time of rest and intellectual work cannot hide the evidence of considerable activity. During this time, Flusser published several essays in the leading German newspaper of Alto Adige/Südtirol in northern Italy, Dolomiten, and one article for Das Fenster of North Tyrol in Austria. These quickly brought him into a number of contemporary multilingual discussions. The essays reprinted here date from that time in the early 1970s and make reference to the immediate context. It is worth noting that 1972 was exactly the year Alto Adige/Südtirol / South Tyrol (officially: Provincia Autonoma di Bolzano/ Autonome Provinz Bozen/Provinzia Autonoma de Balsan/Bulsan) successfully adopted a policy of détente. As Flusser had several well-informed and educated friends in Italy, and as the Italian and German newspapers frequently reported on the issue, he must have known details of those developments. -
31St International Epilepsy Congress Istanbul, Turkey 5Th – 9Th September 2015
ABSTRACTS 31st International Epilepsy Congress Istanbul, Turkey 5th – 9th September 2015 Epilepsia, 56(Suppl. 1):3–263, 2015 doi: 10.1111/epi.13241 Platform Session: Basic Science 0002 Sunday, 6th September 2015 MORPHOLOGICAL CHANGES IN EEG, AQUAPORIN- 4, C-FOS AND THE HIPPOCAMPUS OF ANIMAL 0001 MODELS WITH TEMPORAL LOBE EPILEPSY SODIUM SELENATE RETARDS EPILEPTOGENESIS INDUCED BY KAINIC ACID ı † † † ‡ VIA ACTIVATING PROTEIN PHOSPHATASE 2A E. Taskiran*,C.Ylmaz , N. Orhan , M. Bahceci , M. Kaya , B. Ahishali‡, M. Kucuk†, N. Arican‡, C. Gurses§ P. Zheng*, S. Liu*, N. Jones*, S. Shultz*, G. Dezsi*, D. Wright†, *Neurology Department, Istanbul Medipol University, Istanbul, C. Hovens‡, T.J. O’Brien*,§ † *The Royal Melbourne Hospital, Medicine, Melbourne, Turkey, Istanbul University, Research Institute of Experimental Medicine, Istanbul, Turkey, ‡Istanbul University Istanbul Australia, †The Florey Institutes of Neuroscience and Mental Faculty of Medicine, Istanbul, Turkey, §Department of Health, Melbourne, Australia, ‡The Royal Melbourne Hospital, Surgery, Melbourne, Australia, §Melbourne Brain Centre, Neurology and Clinical Neurophysiology, Istanbul University, Neurology, Melbourne, Australia Istanbul Faculty of Medicine, Istanbul, Turkey Purpose: Temporal lobe epilepsy (TLE) is the most frequent type of Purpose: Epileptogenesis describes the neurobiological processes that localization-related focal epilepsy seen in humans. It has a frequency rate convert a healthy brain into an epileptic brain. There are no treatments of 30–35% among all epilepsies, and comprises 70% of intractable available to mitigate epileptogenesis in clinical practice. Down-regula- epilepsies. With hippocampal sclerosis as the most often observed tion of protein phosphatase 2A (PP2A) activity increases phosphorylated histopathological finding, its epileptogenesis is still researched. tau (p-tau), which is implicated in acquired epilepsy. -
001 | Cerebrospinal Fluid Profile in Epilepsy Considering Exclusion Of
DOI: 10.1111/epi.14612 ABSTRACT ADULT EPILEPTOLOGY etiology and seizure type. This is most important to prevent 27 AUGUST 2018 misinterpretation of postictal phenomena of CSF parame- ters. Nevertheless, one should note, that mild pleocytosis 001 | Cerebrospinal Fluid Profile in Epilepsy and/or intrathecal Ig is found only in a minor percentage of patients, indicating careful exclusion of alternative reasons Considering Exclusion of an Autoimmune Origin for alterations in CSF profile. M. Süße*, N. Saathoff†, M. Hannich*, C. Holbe*, A. Dressel‡, A. Flöel§, F. von Podewils* *University Medicine Greifswald, Neurology/Epileptology, Greifswald, Germany; †University Medicine Greifswald, Greifswald, Germany; 002 | Automated Free‐Water Imaging Analysis ‡ § Carl‐Thiem Klinikum Cottbus, Neurology, Cottbus, Germany; University in Patients with Epilepsy and Focal Cortical Medicine Greifswald, Neurology, Greifswald, Germany Dysplasia Purpose: Analyzing cerebrospinal fluid (CSF) is crucial in B.A.K. Kreilkamp*,†, O. Pasternak‡, K. Das†, U.C. Wieshmann†, † ,† ,† the diagnostic workup of epileptic seizures, in particular to S. Biswas , A.G. Marson* , S.S. Keller* *University of Liverpool, Liverpool, United Kingdom; †The Walton Centre investigate the occurrence of infectious diseases or autoim- ‡ mune epilepsy in cases of encephalitis. It is, therefore, essen- NHS Foundation Trust, Liverpool, United Kingdom; Harvard Medical School, Boston, ME, United States tial to characterize CSF changes caused by epileptic seizures to understand etiological associated pathogenic alterations in Purpose: Focal cortical dysplasia (FCD) may escape neuro- CSF profile. Existing systematic investigations differ in radiologist assessment [Martin et al. QIMS 2015;5(2):188– result and methodology; also the systematic exclusion of 203]. Quantitative lesion detection usually relies on T1w and autoimmune encephalitis is lacking in present studies. -
Literatur-Dauerrecherche Multiple Sklerose Ausgabe Februar 2018
Literatur-Dauerrecherche – 1 – Multiple Sklerose: Veröffentlichungen Oktober 2013 Literatur-Dauerrecherche Multiple Sklerose Ausgabe Februar 2018 Die Literatur-Dauerrecherche finden Sie zum Download auch auf unserer Internetseite http://www.betaferon.de nach der Anmeldung unter dem Reiter „Aktuelle Informationen“, Menüpunkt „MS-Literaturupdate“. Bayer Vital GmbH, Specialty Medicine http://www.gesundheit.bayer.de http://www.betaferon.de Ungefiltert, unredigiert und nach Journals sortierthttp://www.ms -gateway.de Quelle: Public Medline; 288 Abstracts (=Neuaufnahmen in der Literaturdatenbank) Längste Therapieerfahrung 1,2,3,4 EDSS – Berufstätigkeit – Kognition BETAPLUS® Persönliche Patienten-Betreuung BETACONNECT® Innovative Injektionshilfe MEHR ALS 25 JAHRE KLINISCHE ERFAHRUNG 1 Goodin D et al., Neurology 2012;78:1315–1322, 2 Ebers G et al., JNNP 2010;81:907-912, 3 Kappos L et al.,Poster M1715WIP, ANA 2014, 4 Edan G et al., Poster P7.012,AAN 2015 Betaferon® 250 Mikrogramm/ml, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Wirkstoff: Interferon beta-1b (Vor Verschreibung bitte die Fachinformation beachten.) Zusammensetzung: Arzneilich wirksamer Bestandteil: 1 ml der gebrauchsfertigen Injektionslösung enthält 250 Mikrogramm (8,0 Mio. I.E.) rekombinantes Interferon beta-1b. 1 Durchstechfl asche enthält 300 Mikrogramm (9,6 Mio. I.E.) rekombinantes Interferon beta-1b. Sonstige Bestandteile: Pulver für Injektionslösung: Albumin vom Menschen, Mannitol, Lösungsmittel: Natriumchloridlösung 0,54 % G/V. Anwendungsgebiete: Betaferon® -
Programme 2015
London on View The 5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures 9-11 April 2015 London, United Kingdom Final Programme www.statusepilepticus2015.eu PATRONS Paracelsus Medical University Christian Doppler Klinik Ignaz Harrer Strasse 79 A-5020 Salzburg, Austria University College London Institute of Neurology Queen Square London WC 1N 3BG United Kingdom CHAIRS Simon Shorvon, London, United Kingdom Eugen Trinka, Salzburg, Austria 3 Contents Welcome Dear friends and colleagues, WELCOME ......................................................................................................................................... 5 Eugen Trinka Simon Shorvon GENERAL INFORMATION. ................................................................................................................ 6 It is our sincere pleasure to welcome you all to London, to this the 5th London-Innsbruck Col- Information FOR SPEAKERS & POSTER PRESENTERS................................................................... 8 loquium on Status Epilepticus and Acute Seizures. These meetings have taken place biennially since 2007, and have become an important fea- SCIENTIFIC PROGRAMME.................................................................................................................. 9 ture of the epilepsy calendar. ThursdaY, 9 APRIL 2015 ................................................................................................... 9 This year, the conference will focus on the clinical and experimental nature of status epilepti- cus